Perseon Presents Key Microwave Ablation Findings at STM 2015
April 21 2015 - 9:15AM
Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a
leading provider of medical systems that utilize energy to treat
cancer, today announced its participation as a presenter last week
at STM 2015: The 32nd Annual Meeting of the Society for Thermal
Medicine, held in Orlando, Florida.
Representing Perseon, Senior Scientist Mark J. Hagmann Ph.D.
presented "Principles for Accurate Simulations of Microwave
Ablation" during STM's Thermal Modeling and Devices Symposium held
on April 15th. Dr. Hagmann demonstrated how Perseon's methods,
utilizing MicroThermX® technology, can better predict and optimize
cancer treatment options and patient outcomes.
"Mark is a renowned thought leader in energy ablation and his
remarks at STM 2015 demonstrate Perseon's ongoing recognition as a
leading innovator," said Clint Carnell, CEO of Perseon. "Our
participation at STM 2015 illustrates our focus on marketing and
education initiatives that advance the understanding of our market
leading technology."
Dr. Hagmann received a Ph.D. in Electrical Engineering from the
University of Utah on "Numerical Studies of absorption of
electromagnetic Energy by Man" (1981), followed by five years
(1982-1986) studying microwave hyperthermia as a Senior Staff
Fellow at the National Institutes of Health (NIH), and 14 years
(1986-2000) as a Professor in Electrical and Computer Engineering
at Florida International University. Dr. Hagmann has worked
for Perseon since 2000, and he is a member of the American Physical
Society, the Institute of Electrical and Electronics Engineers
(IEEE), and a Fellow in the Electromagnetics Academy. Mark
has 124 publications in refereed technical and scientific journals,
and has given 289 presentations at international
meetings.
About Perseon
Perseon Corporation invests its resources in fighting humanity's
worst disease: cancer. Perseon's people are dedicated to finding
innovative technologies and means to deliver energy solutions to
healthcare providers and patients around the world. MicroThermX®
treats soft tissue tumors with precision-focused energy, expanding
the options and broadening the opportunities for cancer
treatment.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our intent to
divest our hyperthermia business in Spring 2015, focus on microwave
ablation to create stockholder value, comply with Nasdaq continued
listing requirements, generate capital from a transaction related
to our building and pursue other strategic plans are
forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties, including the risk that for a
variety of reasons we may not be able to execute on our strategic
plans, and other risks and uncertainties detailed in the Company's
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date on which such
statements are made, and the Company undertakes no obligation to
update such statements to reflect events or circumstances arising
after such date, except as required by law.
CONTACT: Tricia Ross
Financial Profiles
310-622-8226
tross@finprofiles.com